Stuart M. Grant Acquires 100,000 Shares of Eyenovia, Inc. (NASDAQ:EYEN) Stock

Eyenovia, Inc. (NASDAQ:EYEN) major shareholder Stuart M. Grant bought 100,000 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The shares were bought at an average price of $0.98 per share, for a total transaction of $98,000.00. Following the completion of the acquisition, the insider now owns 5,430,715 shares in the company, valued at approximately $5,322,100.70. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Eyenovia Stock Performance

Shares of NASDAQ:EYEN remained flat at $0.99 on Thursday. The stock had a trading volume of 786,734 shares, compared to its average volume of 927,150. The firm has a market capitalization of $46.73 million, a P/E ratio of -1.49 and a beta of 1.72. The company’s 50 day moving average price is $1.69 and its 200-day moving average price is $1.61. Eyenovia, Inc. has a 12 month low of $0.92 and a 12 month high of $5.85. The company has a quick ratio of 2.16, a current ratio of 2.17 and a debt-to-equity ratio of 1.00.

Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings results on Monday, March 18th. The company reported ($0.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.17). During the same quarter last year, the business earned ($0.17) earnings per share. Equities analysts expect that Eyenovia, Inc. will post -0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a report on Tuesday, March 19th.

Institutional Investors Weigh In On Eyenovia

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in Eyenovia during the 4th quarter worth approximately $26,000. Two Sigma Securities LLC bought a new position in Eyenovia during the second quarter valued at approximately $27,000. Goldman Sachs Group Inc. acquired a new stake in shares of Eyenovia in the 2nd quarter valued at $28,000. Prudential Financial Inc. bought a new stake in shares of Eyenovia during the 2nd quarter worth about $33,000. Finally, Leo Wealth LLC acquired a new position in Eyenovia during the fourth quarter valued at approximately $34,000. 25.84% of the stock is owned by institutional investors and hedge funds.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.